Selección de publicaciones

  • Rabal, O.; Oyarzabal, J.* Biologically Relevant Chemical Space Navigator: From Patent and Structure-Activity Relationship Analysis to Library Acquisition and Design. Journal of Chemical Information and Modeling, 2012, 52, 3123 – 3137. IF: 4.304 (2012); Lugar: 3/100; Computer science, interdisciplinary applications; 1er cuartil.

  • Ugarte, A.; Gil-Bea, F.; García-Barroso, C.; Cedazo-Minguez, A.; Ramírez, M. J.; Franco R.; García-Osta, A.; Oyarzabal, J.;* Cuadrado-Tejedor, M.* Decreased levels of cGMP in CSF are associated with cognitive decline and amyloid pathology in Alzheimer's disease. Neuropathology Applied Neurobiololgy. 2015, 41, 471-482;  IF: 3.927 (2014); Lugar: 33/192; Neurology, clinical; 1er cuartil.

  • Orbe, J.; Sanchez-Arias, J. A.; Rabal, O.; Rodríguez, J. A.; Salicio, A.; Ugarte, A.; Belzunce, M.; Xu, M.; Wu, W.; Tan, H.; Ma, H.; Paramo, J. A.;* Oyarzabal, J.* Design, synthesis and biological evaluation of novel matrix metalloproteinase inhibitors as  potent antihemorrhagic agents: from hit identification to an optimized lead. Journal of Medicinal Chemistry, 2015, 58, 2465-2488; IF: 5.447 (2014); Lugar: 3/59; Chemistry, medicinal; 1er cuartil.

  • Orbe, J.; Rodríguez, J. A; Sanchez-Arias, J. A; Salicio, A.; Belzunce, M.; Ugarte, A; Chang, H.C.Y.; Rabal, O; Oyarzabal, J;* Paramo, J. A* Novel Discovery and safety profiling of a potent pre-clinical candidate, 4-[4-[[(3R)-3(hydroxycarbamoyl) -8-azaspiro[4.5]decan-3-yl]sulfonyl]phenoxy]-N-methyl-benzamide (CM-352), for the prevention and treatment of hemorrhage. Journal of Medicinal Chemistry, 2015, 58, 2941-2957; IF: 5.447 (2014); Lugar: 3/59; Chemistry, medicinal; 1er cuartil.

  • Allende M, Molina E, Guruceaga E, Tamayo I, González-Porras JR, Gonzalez-López TJ, Toledo E, Rabal O, Ugarte A, Roldán V, Rivera J, Oyarzabal J, Montes R, Hermida J. Hsp70 protects from stroke in atrial fibrillation patients by preventing thrombosis without increased bleeding risk. Cardiovasc Res 2016; 1;110(3):309-18. IF: 5.878 (2016); Lugar: 16/128, 1er cuartil.

  • Rabal O, Sánchez-Arias JA, Cuadrado-Tejedor M, de Miguel I, Pérez-González M, García-Barroso C, Ugarte A, Estella-Hermoso de Mendoza A, Sáez E, Espelosin M, Ursua S, Haizhong T, Wei W, Musheng X, Garcia-Osta A, Oyarzabal J. Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease. J Med Chem. 2016 Oct 13;59(19):8967-9004. IF: 6.253 (2017); Lugar: 3/59, 1er cuartil.

  • Sánchez-Arias JA, Rabal O, Cuadrado-Tejedor M, de Miguel I, Pérez-González M, Ugarte A, Sáez E, Espelosin M, Ursua S, Haizhong T, Wei W, Musheng X, Garcia-Osta A, Oyarzabal J. Impact of Scaffold Exploration on Novel Dual-Acting Histone Deacetylases and Phosphodiesterase 5 Inhibitors for the Treatment of Alzheimer's Disease. ACS Chem Neurosci. 2017 Mar 15;8(3):638-661. IF: 4.211 (2017); Lugar: 67/293, 1er cuartil.

  • Rabal O, Sánchez-Arias JA, Cuadrado-Tejedor M, de Miguel I, Pérez-González M, García-Barroso C, Ugarte A, Estella-Hermoso de Mendoza A, Sáez E, Espelosin M, Ursua S, Haizhong T, Wei W, Musheng X, Garcia-Osta A, Oyarzabal J. Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease. Eur J Med Chem. 2018 Apr 25;150:506-524. IF: 4.816 (2017); Lugar: 4/59, 1er cuartil.



"Nuestro fin es descubrir nuevas terapias moleculares que puedan cubrir necesidades médicas no resueltas, basándonos en nuevas dianas o/y mecanismos de acción aportados por los investigadores del CIMA y de la Clínica Universidad de Navarra", Dr. Julen Oyarzabal, director del programa.

Contactar

Contacto:
Cristina Canciani
Avda. Pío XII, 55
31008 Pamplona
España

(+34) 948 194 700 Ext. 2013
canciani@unav.es